NewLink Genetics Corporation
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, NewLink Genetics Corporation sits in the top decile of US sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count).
NewLink Genetics Corporation: 31 sponsored US clinical trials, none currently recruiting.
NewLink Genetics Corporation sponsors 31 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 17 completed. 2 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Large Cell Carcinoma, with 1 trials.
Top-decile sponsor footprint
NewLink Genetics Corporation ranks in the top decile of sponsors by registered trial count (#526 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
31 total, page 1 of 1
Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers
NCT03852446
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
NCT03301636
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
NCT03165188
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
NCT03164603
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02835729
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
NCT02460367
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
NCT02502708
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
NCT02648711
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT02389985
Immunotherapy Study for Metastatic Renal Cell Cancer
NCT02035358
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
NCT02405585
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
NCT02380677
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02077881
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
NCT02187302
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
NCT02073123
Immunotherapy Study for Patients With Stage IV Melanoma
NCT02054520
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
NCT02052648
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
NCT01836432
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
NCT01792050
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
NCT01774578
Immunotherapy Study for Surgically Resected Pancreatic Cancer
NCT01072981
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NCT00739609
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
NCT00614601
Vaccine Study for Surgically Resected Pancreatic Cancer
NCT00569387
Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
NCT00420732
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
NCT00333502
Vaccine Treatment for Advanced Malignant Melanoma
NCT00300612
Vaccine Treatment for Surgically Resected Pancreatic Cancer
NCT00255827
Vaccine Treatment for Hormone Refractory Prostate Cancer
NCT00105053
Vaccine Treatment for Advanced Breast Cancer
NCT00090480
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NCT00073398
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 9 |
| Phase 3 | 2 |
Therapeutic Areas
How the NewLink Genetics Corporation early-phase archive is shaped
31 indexed studies, none listed as recruiting (0% open); 17 completed (55%).
Phase mix: 2 late (III/IV) vs 28 early (I/II) (early-phase heavy).
Top condition: Large Cell Carcinoma (1 trial), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
NewLink Genetics Corporation: archived-pipeline peers nationwide
Peers matched on 31 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
NewLink Genetics Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 31 archived trials
- Children's Hospitals and Clinics of Minnesota · 31 trials · 10% recruiting
- Cook Group Incorporated · 31 trials · 0% recruiting
- Cytokinetics · 31 trials · 10% recruiting
- Halozyme Therapeutics · 31 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this NewLink Genetics Corporation page
31 registered trials is a research-attention snapshot, not an endorsement of NewLink Genetics Corporation or any single study.
- None of NewLink Genetics Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Large Cell Carcinoma is the condition NewLink Genetics Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Large Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. NewLink Genetics Corporation pipeline card: 31 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.